Becton Dickinson and Medi-Ject modify strategic alliance and remain partners
This article was originally published in Clinica
Executive Summary
Becton Dickinson is to return manufacturing and marketing rights for a development-stage needle-free injector system to Medi-Ject, while retaining an option on another injection system, which is at an earlier development stage. Under the revised terms of their strategic partnership, Becton has an option to manufacture the disposable syringe part of the device, if Medi-Ject's sales increase sufficiently to warrant Becton's large-volume capacities.